Bayer Investor Relations

Team having a chat
Investor News
Share Price / Index
July 21, 2025
Not intended for U.S. and UK Media
Bayer’s Nubeqa™ (darolutamide) receives EU approval in third indication for patients with advanced prostate cancer
July 16, 2025
Far-reaching transformation advancing, delivering first signs of success:
Supervisory Board of Bayer AG extends contract of CEO Bill Anderson
July 14, 2025
Not intended for U.S. and UK Media
U.S. FDA Approves Finerenone for New Indication in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥ 40%